Astrazeneca.ca
Health Canada approves Lynparza in combination with abiraterone …
Conditional approval based on data from Phase 3 PROpel trial. MISSISSAUGA, ON – July 13, 2023 – Health Canada has granted a Notice of Compliance with Conditions (NOC/c) for Lynparza® (olaparib) in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic
Actived: Just Now
Top Categories
Popular Searched
› Cpso sauble family health team
› Superior healthcare management linkedin
› Healthy quick snacks to make
› Hotels near uc health anschutz
› Working the night shift mental health
› 2 tier health insurance system
Recently Searched
› Devilbiss health care uk ltd
› Inter valley health plan scam
› Superior health plan website
› Caregiving mental health services
› Heart healthy valentine gifts